Last year 23andMe and Genentech launched an online study of metastatic breast cancer to learn more about what role genes might play in how a person responds to bevacizumab, also known as Avastin ®. (Avastin ® is not approved by the FDA for treatment of metastatic breast cancer.)
We were happy with the positive response from metastatic breast cancer patients, and are excited to announce that Genentech and 23andMe are expanding the eligibility requirements for this research.
Starting today, the InVite study is open to any patient in the U.S. who used Avastin prior to 2013 for treatment of metastatic colorectal cancer, metastatic non-squamous non-small cell lung cancer, relapsed glioblastoma, metastatic renal cell carcinoma, or metastatic breast cancer.Our goal is to recruit 1,000 people to participate in this study. InVite study participants will be asked to send a saliva sample for genetic analysis and to complete up to five short online surveys over the course of a year about their cancer as well as their experience with Avastin. Participants also have the opportunity to provide an optional blood sample for additional analyses.
By combining participants’ genetic data with survey responses, we hope to discover new genetic markers for these advanced diseases, and to understand why some people respond well to treatment when others do not. 23andMe is excited about partnering with Genentech on this new and innovative web-based approach to data collection and research process.(While this study may generate important scientific findings, participants should not expect that these findings will change how they are or have been treated for their disease.)
We appreciate the strong partnerships of breast cancer advocacy groups that have supported and raised awareness for the InVite Study over the last year. These groups include the Avon Foundation for Women, BreastCancer.Org, Living Beyond Breast Cancer, the Metastatic Breast Cancer Network, the Triple Negative Breast Cancer Foundation, the Cancer Support Community, Facing Our Risk for Cancer Empowered (FORCE), EmpowHER, and Stand Up To Cancer. As we expand the study, we are excited to announce new partnerships with the Kidney Cancer Association, LUNGevity, Fight Colorectal Cancer, National Lung Cancer Partnership, Colon Cancer Alliance, and the Musella Foundation.